Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Incyte Corp (NASDAQ:INCY)

76.98
Delayed Data
As of Jun 24
 -4.68 / -5.73%
Today’s Change
55.00
Today|||52-Week Range
133.62
-29.02%
Year-to-Date
Incyte Gains on Jakafi's Breakthrough Status for Acute GVHD
Jun 24 / Zacks.com - Paid Partner Content
Better Buy: Johnson & Johnson vs. Eli Lilly
Jun 15 / MotleyFool.com - Paid Partner Content
Incyte Reports Epacadostat Combination Study Initiation
Jun 23 / Zacks.com - Paid Partner Content
Should Pfizer Buy This Beaten-Down Immuno-Oncology Company?
Jun 14 / MotleyFool.com - Paid Partner Content
Incyte Gets FDA Approval For Breakthrough Therapy Status For Its Ruxolitinib
Jun 23 / Benzinga - Paid Partner Content
 

Today’s Trading

Previous close81.66
Today’s open76.84
Day’s range76.41 - 80.89
Volume2,384,331
Average volume (3 months)1,369,673
Market cap$14.4B
Dividend yield--
Data as of 4:00pm ET, 06/24/2016

Growth & Valuation

Earnings growth (last year)--
Earnings growth (this year)-38.33%
Earnings growth (next 5 years)+118.55%
Revenue growth (last year)+47.36%
P/E ratio302.7
Price/Sales26.95
Price/Book83.95

Competitors

 Today’s
change
Today’s
% change
PRGOPerrigo Company PLC-4.19-4.40%
BMRNBiomarin Pharmaceuti...-6.64-7.94%
MDVNMedivation Inc-2.31-3.90%
VRTXVertex Pharmaceutica...-6.30-7.14%
Data as of 4:04pm ET, 06/24/2016

Financials

Next reporting dateJuly 28, 2016
EPS forecast (this quarter)$0.00
Annual revenue (last year)$753.8M
Annual profit (last year)$6.5M
Net profit margin0.87%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Hervé Hoppenot
Chief Financial Officer &
Executive Vice President
David W. Gryska
Corporate headquarters
Wilmington, Delaware

Forecasts

Partner Offers

Search for Jobs